Officer stock option holdings disclosed at Aligos Therapeutics (ALGS)

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. reported the initial holdings of Principal Accounting Officer Nikhil Aneja on a Form 3. The filing lists several stock option awards giving the right to buy 3,800, 2,640, 7,155 and 3,600 shares, each vesting over four years based on continued service.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Aneja Nikhil

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 3,800 shares (Direct)

Footnotes (1)

1. 25% of the total number of shares vest in one year and 1/36th of the remaining total number of shares vest in thirty-six (36) successive and equal monthly installments measured one year following February 13, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Aneja Nikhil

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/29/2026

3. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	02/13/2034	Common Stock	3,800	$16	D
Stock Option (Right to Buy)	(2)	09/04/2034	Common Stock	2,640	$11.74	D
Stock Option (Right to Buy)	(3)	02/28/2035	Common Stock	7,155	$16.87	D
Stock Option (Right to Buy)	(4)	07/16/2035	Common Stock	3,600	$8.68	D

Explanation of Responses:

1. 25% of the total number of shares vest in one year and 1/36th of the remaining total number of shares vest in thirty-six (36) successive and equal monthly installments measured one year following February 13, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

2. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

3. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

4. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Lesley Ann Calhoun, as attorney-in fact for Nikhil Aneja	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Aligos Therapeutics (ALGS) Form 3 for Nikhil Aneja show?

The Form 3 for Aligos Therapeutics (ALGS) reports Principal Accounting Officer Nikhil Aneja’s initial holdings of several stock option grants. These options provide rights to buy company shares and are subject to multi‑year vesting tied to continued employment.

Are there any stock purchases or sales in the Aligos Therapeutics (ALGS) Form 3?

No, the Aligos Therapeutics (ALGS) Form 3 does not report stock purchases or sales. It simply lists existing stock option holdings for officer Nikhil Aneja, describing the vesting schedules for each grant over a four‑year period.

How do Nikhil Aneja’s stock options at Aligos Therapeutics (ALGS) vest?

The listed stock options for Nikhil Aneja vest over four years. One grant vests 25% after one year, then monthly over three years, while others vest in equal monthly installments over 48 months from their respective vesting commencement dates.

What role does Nikhil Aneja hold at Aligos Therapeutics (ALGS)?

In this filing, Nikhil Aneja is identified as the Principal Accounting Officer of Aligos Therapeutics (ALGS). The Form 3 discloses his initial beneficial ownership in the company through various stock option awards with specified vesting schedules.

Why is Aligos Therapeutics (ALGS) filing a Form 3 for its officer?

Aligos Therapeutics (ALGS) files a Form 3 to disclose the initial beneficial ownership of an insider, here Principal Accounting Officer Nikhil Aneja. It provides transparency on his stock option positions and how they vest over time, as required for new reporting persons.